Tanir Ferdi, Mete Burak, Demirhindi Hakan, Kara Ertan, Nazlican Ersin, Dağlıoğlu Gülçin, Kibar Filiz, Çetiner Salih, Kanat Ceren
Department of Public Health, Faculty of Medicine, Çukurova University, Adana 01330, Turkey.
Central Laboratory, Balcalı Hospital, Faculty of Medicine, Çukurova University, Adana 01330, Turkey.
Vaccines (Basel). 2022 Jul 25;10(8):1177. doi: 10.3390/vaccines10081177.
This prospective cohort study aimed to evaluate the efficacy of COVID-19 vaccine schemes, homologous versus heterologous vaccine strategies, and vaccine-induced anti-S-RBD-IgG antibody response in preventing COVID-19 among 942 healthcare workers 1 year after vaccination with the inactivated and/or mRNA vaccines. All participants received the first two primary doses of vaccines, 13.6% of them lacked dose 3, 50.5% dose 4, and 90.3% dose 5. Antibody levels increased with the increase in number of vaccine doses and also in heterologous vaccine regimens. In both inactive, mRNA vaccines and mixed vaccination, infection rates were significantly higher in two-dose-receivers, but lower in four- or five-dose receivers and increasing the total number of vaccine doses resulted in more protection against infection: the three-dose regimen yielded 3.67 times more protection, the four-dose 8 times, and five-dose 27.77 times more protection from COVID-19 infection, compared to any two-dose vaccination regimens. Antibody levels at the end of the first year of four- or five-dose-receivers were significantly higher than two- or three-dose receivers. To conclude, an increased number of total vaccine doses and anti-S-RBD antibody levels increased the protection from COVID-19 infection. Therefore, four or more doses are recommended in 1 year for effective protection, especially in risk groups.
这项前瞻性队列研究旨在评估新冠病毒疫苗接种方案（同源与异源疫苗策略）以及接种灭活疫苗和/或mRNA疫苗1年后，疫苗诱导的抗S-RBD-IgG抗体反应在942名医护人员中预防新冠病毒感染的效果。所有参与者均接种了前两剂主要疫苗，其中13.6%的人未接种第三剂，50.5%未接种第四剂，90.3%未接种第五剂。抗体水平随着疫苗接种剂量的增加以及异源疫苗接种方案而升高。在灭活疫苗、mRNA疫苗以及混合接种中，接种两剂疫苗者的感染率显著更高，但接种四剂或五剂者的感染率更低，增加疫苗接种总剂量可提供更多的感染防护：与任何两剂接种方案相比，三剂接种方案提供的防护高3.67倍，四剂高8倍，五剂高27.77倍。接种四剂或五剂者在接种后第一年年底时的抗体水平显著高于接种两剂或三剂者。总之，增加疫苗接种总剂量以及抗S-RBD抗体水平可增强对新冠病毒感染的防护。因此，建议在1年内接种四剂或更多剂次以获得有效防护，尤其是在高危人群中。
